Patents by Inventor Michael Nathaniel Alonso

Michael Nathaniel Alonso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY ADJUVANT CONJUGATES
    Publication number: 20230111340
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Application
    Filed: August 8, 2022
    Publication date: April 13, 2023
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • Antibody adjuvant conjugates
    Patent number: 11547761
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: January 10, 2023
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Bolt Biotherapeutics, Inc.
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • Antibody adjuvant conjugates
    Patent number: 11110178
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 7, 2021
    Assignees: The Board of Trustees of the Leland Standford Junior University, BOLT BIOTHERAPEUTICS, INC.
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • ANTIBODY ADJUVANT CONJUGATES
    Publication number: 20200206357
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • Antibody adjuvant conjugates
    Patent number: 10675358
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 9, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Bolt Biotherapeutics, Inc.
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • Methods and Compositions for Dectin-2 Stimulation and Cancer Immunotherapy
    Publication number: 20200140556
    Abstract: Provided are methods and compositions for treating an individual with cancer or infectious disease. Multivalent Dectin-2 stimulating agents are provided that include: (a) an agent that binds to Dectin-2 and stimulates Dectin-2 signaling; and (b) an antibody and/or an immunomodulatory agent, wherein (a) and (b) are conjugated to one another. In some cases, (a) is a mannobiose glycopolypeptide that binds to Dectin-2. In some cases (b) is a stimulatory ligand for a TLR (e.g., TLR7, TLR8, TLR7/8, TLR2, and the like). Methods of treating an individual with cancer and/or an infectious disease can include administering to the individual an effective amount of a Dectin-2 stimulating composition. In some cases, the Dectin-2 stimulating composition comprises a Dectin-2 stimulating glycopolymer. In some cases the Dectin-2 stimulating composition comprises a multivalent Dectin-2 stimulating agent.
    Type: Application
    Filed: June 27, 2018
    Publication date: May 7, 2020
    Inventors: Justin KENKEL, Matthew ZHOU, Shelley Erin ACKERMAN, Edgar George ENGLEMAN, Michael Nathaniel ALONSO, Carolyn R. BERTOZZI
  • ANTIBODY ADJUVANT CONJUGATES
    Publication number: 20200108151
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker which comprises an ethylene glycol group or glycine residue. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 9, 2020
    Applicant: Bolt Biotherapeutics, Inc.
    Inventors: David Y. Jackson, Michael Nathaniel Alonso, Arthur Lee
  • ANTIBODY ADJUVANT CONJUGATES
    Publication number: 20190076547
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via, the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Application
    Filed: September 24, 2018
    Publication date: March 14, 2019
    Inventors: Michael Nathaniel Alonso, Edgar George Engleman, Shelley Erin Ackerman, Justin Kenkel, Arthur Lee, David Y. Jackson
  • ANTIBODY ADJUVANT CONJUGATES
    Publication number: 20190015516
    Abstract: The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker which comprises an ethylene glycol group or glycine residue. Methods for treating cancer with the immunoconjugates of the invention are also described.
    Type: Application
    Filed: September 12, 2018
    Publication date: January 17, 2019
    Applicant: Bolt Biotherapeutics, Inc.
    Inventors: David Y. Jackson, Michael Nathaniel Alonso, Arthur Lee